Barclays PLC Increases Position in Agenus Inc. (NASDAQ:AGEN)

Barclays PLC increased its holdings in shares of Agenus Inc. (NASDAQ:AGEN) by 295.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,813 shares of the biotechnology company’s stock after purchasing an additional 20,777 shares during the quarter. Barclays PLC’s holdings in Agenus were worth $152,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. HighTower Advisors LLC lifted its position in shares of Agenus by 46.1% in the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after buying an additional 7,530 shares in the last quarter. FMR LLC raised its holdings in shares of Agenus by 47.1% in the third quarter. FMR LLC now owns 85,301 shares of the biotechnology company’s stock worth $467,000 after buying an additional 27,309 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Agenus by 2,271.5% during the third quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock valued at $217,000 after purchasing an additional 37,866 shares during the period. Federated Hermes Inc. bought a new position in Agenus in the 2nd quarter worth about $1,921,000. Finally, State Street Corp increased its holdings in Agenus by 2.1% during the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock worth $2,563,000 after purchasing an additional 9,731 shares during the period. Institutional investors own 61.46% of the company’s stock.

Agenus Trading Up 7.3 %

Shares of AGEN opened at $3.55 on Wednesday. Agenus Inc. has a 12 month low of $2.50 and a 12 month high of $19.69. The stock has a fifty day moving average price of $3.25 and a 200-day moving average price of $5.87. The firm has a market cap of $83.28 million, a PE ratio of -0.32 and a beta of 1.27.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating on shares of Agenus in a report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $10.00.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.